We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Topics Covered
- The development of naked and drug-conjugated antibodies against endoglin and CD75b
- The results of recent clinical trials with both therapeutic antibodies
- Advantages and challenges in the development of naked and drug-conjugated antibodies
Biography
Ben K. Seon is a Professor of Immunology and Oncology. He is a nationally and internationally recognized cancer researcher whose main research has been on the development of unique monoclonal antibodies that define novel tumor associated antigens or novel epitopes of tumor associated antigens and application of these monoclonal antibodies and their immunoconjugates for cancer therapy. Recent focus of his studies has been on translational research in the fields of antibody-based anti-angiogenic and vascular targeting therapy of cancer by targeting endoglin (CD105), which he co-discovered.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Seon, B. (2020, September 16). The development of therapeutic antibodies against oncogenic antigens [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 3, 2024, from https://doi.org/10.69645/JYDV6418.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Ben Seon has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Playlist: Research and Clinical Interviews
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Professor Seon, thank you very much for taking
the time to record this interview with us today.
So my first question is,
what has happened since the recording of your talk
on human tumor antigens as therapeutic targets
of cancer, with regards to
the clinical applications of the relevant discoveries from your lab?
Professor Seon: Since my last talk on TRC105,
we made substantial progress in the sense of patient therapy.
So today, I'm going to talk about two anti-cancer antibodies developed in my laboratory,
and tested in many trials of cancer patients.
One is TRC105, the other one is Carotuximab vedotin.
Carotuximab vedotin is a drug conjugate.
So, I'm going to talk about these two different antibodies.
First, TRC105 is a human/mouse chimeric monoclonal antibody,
therefore it's termed TRC105.
They were generated in my laboratory and licensed to Tracon Pharma,
it's a small company in San Diego.
Now, TRC105 reacts with endocrine.
That is strongly expressed on the surface of
proliferating endothelial cells of tumor blood vessels.
Also, it reacted with a certain type of tumor cells such as